Invesco’s Neuropace NPCE Stock Holding History

Invesco’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227K	Buy	14,302 +3,628	+34%	+$58.4K	﹤0.01%	3541
2026 Q1	$140K	Sell	10,674 -1,265	-11%	-$19K	﹤0.01%	3580
2025 Q4	$184K	Buy	+11,939	New	+$160K	﹤0.01%	3550

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Invesco's NPCE Position: Q2 2026 in Review

Invesco increased its Neuropace (NPCE) stake by 34% in Q2 2026, buying an estimated $58.4K and bringing the position to 14,302 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #3541.

Invesco first reported a position in NPCE in Q4 2025 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

Invesco held 14,302 shares of Neuropace worth $227K as of Q2 2026.
Invesco bought 3,628 Neuropace shares in Q2 2026, an estimated $58.4K.
Neuropace made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3541 holding.
Invesco first reported a position in Neuropace in Q4 2025 and has held it in 3 quarters since.
113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.